Compare Cognizant Technology Solutions Corp (CTSH) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs 10X Genomics Inc — how do they compare? Cognizant Technology Solutions Corp trades at $43.17 (market cap $20.34B), while 10X Genomics Inc trades at $46.33 (market cap $5.81B). The key difference: Cognizant Technology Solutions Corp is far larger — about 3.5× 10X Genomics Inc's market cap, and Cognizant Technology Solutions Corp pays a 3.07% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| CTSH | TXG | |
|---|---|---|
Market Cap | $20.34B | $5.81B |
Sector | Technology | Health |
52-Week High | $86.70 | $45.80 |
52-Week Low | $38.73 | $11.34 |
Enterprise Value | $19.92B | $5.36B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant (CTSH) trades at $44.16, up 3.74% today, with a bullish technical signal and strong support at $44. The stock shows solid fundamentals with a P/E of 9.58, revenue of $21.11B in 2025, and consistent earnings beats. Recent news highlights AI partnerships with Google Cloud and OpenAI, positioning the company for growth in enterprise AI services.
The outlook is positive with a consensus price target of $63.45, implying significant upside. Risks include competitive pressures and macroeconomic softness affecting demand. Analyst sentiment is mixed but leans bullish, with 43% buy ratings. The stock presents a value opportunity given its low valuation multiples and strategic AI investments.
TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.
The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
